A baby's cord blood is a rich source of stem cells, which are the body's "master cells." These are genetically unique building blocks for blood, organs, tissue, and the immune system. Stem cells reproduce and differentiate into other cell types, including bone, heart, muscle, and nerve. In transplantation, stem cells differentiate into red blood cells, white blood cells, and platelets, the three types of cells necessary for healthy blood and a sound immune system. Parents who choose to bank their baby's cord blood preserve a unique biological resource that is similar to a "self-repair kit" for a child.
About StemCyte, Inc.
Located in the US, India and Taiwan, StemCyte has established one of the largest, most racially diverse, and highest quality cord blood stem cell banks in the world. StemCyte has supplied over 1000 cord blood products for over 40 life-threatening diseases to over 200 leading worldwide transplant centers. StemCyte is actively involved in the development of new umbilical cord blood-based cell therapies. They are supporting the largest clinical study for using unrelated cord blood transplantation for thalassemia, one of the most common genetic diseases in the world, and supporting trials investigating regenerative spinal cord therapies. StemCyte is contracted by the US Department of HHS to help establish a public National Cord Blood Inventory for unrelated transplant units. Its headquarters are located in Covina, CA and Ewing, NJ.
To learn more about StemCyte, visit www.StemCyte.com.
|SOURCE StemCyte, Inc.|
Copyright©2009 PR Newswire.
All rights reserved